ConvaTec Group’s (CTEC) “Hold” Rating Reaffirmed at Peel Hunt
Other equities research analysts have also issued research reports about the company. Numis Securities reaffirmed a hold rating and issued a GBX 180 ($2.49) price target on shares of ConvaTec Group in a research report on Thursday, February 15th. Citigroup reaffirmed a neutral rating and issued a GBX 226 ($3.12) price target on shares of ConvaTec Group in a research report on Friday, February 16th. Credit Suisse Group reduced their price target on ConvaTec Group from GBX 225 ($3.11) to GBX 215 ($2.97) and set a neutral rating on the stock in a research report on Thursday, February 15th. Morgan Stanley reaffirmed an overweight rating and issued a GBX 249 ($3.44) price target on shares of ConvaTec Group in a research report on Friday, February 23rd. Finally, Deutsche Bank reaffirmed a sell rating and issued a GBX 180 ($2.49) price target on shares of ConvaTec Group in a research report on Friday, December 1st. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the company’s stock. ConvaTec Group has a consensus rating of Hold and a consensus target price of GBX 241.10 ($3.33).
ConvaTec Group (LON:CTEC) traded down GBX 1 ($0.01) during mid-day trading on Friday, reaching GBX 204.80 ($2.83). The company’s stock had a trading volume of 3,120,000 shares, compared to its average volume of 6,120,000. The firm has a market cap of $3,990.00 and a price-to-earnings ratio of 3,413.33. ConvaTec Group has a 52 week low of GBX 181.40 ($2.51) and a 52 week high of GBX 349.10 ($4.82).
In other ConvaTec Group news, insider Ros Rivaz bought 4,908 shares of the business’s stock in a transaction dated Monday, December 4th. The shares were acquired at an average price of GBX 202 ($2.79) per share, with a total value of £9,914.16 ($13,697.37).
About ConvaTec Group
ConvaTec Group Plc is a medical product and technology company. The Company focuses on therapies for the management of chronic conditions, including products used for advanced chronic and acute wound care, ostomy care, continence and critical care and infusion devices used in the treatment of diabetes and other conditions.
Receive News & Ratings for ConvaTec Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConvaTec Group and related companies with MarketBeat.com's FREE daily email newsletter.